Sanofi's rumored next CEO has his work cut out for him; BioNovion and Genmab team up on immuno-oncology;

@FierceBiotech: Lilly delays its high-risk 'good' cholesterol trial with IMPROVE-IT in mind. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: Star scientist Peter Mueller gets $28M war chest to advance R&D at Pronutria. Article | Follow @JohnCFierce

@DamianFierce: Someone needs to talk to Mark Levin about this sweater situation. More | Follow @DamianFierce

> Sanofi's ($SNY) next CEO, widely rumored to be Bayer healthcare chief Olivier Brandicourt, will inherit a challenging situation upon taking the reins, as the drugmaker faces declining sales, pricing pressure and a tenuous relationship with French authorities. News

> More and more developers of gene therapies are warming up to the idea of annuity payments for their one-time treatments. More

> Dutch biotech BioNovion has paired up with Genmab to develop bispecific antibodies for immuno-oncology. Release

Medical Device News

@FierceMedDev: Lineagen reels in $19.8M in Series C round for autism genetic tests. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Vagus nerve stimulation, other forms of bioelectric medicine on cover of Scientific American. Item | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Boston Scientific hands over $600M to settle breach-of-contract Guidant suit with J&J. Article | Follow @EmilyWFierce

> GE recalls 10,000+ MRIs after FDA deems them potentially deadly, citing poor training. News

> Mayo Clinic joins $20.5M Series A reboot for next-gen sequencing startup Lifecode. Story

> FDA panel considering PMA application of spinal implant due to fractures. Article

Pharma News

@FiercePharma: ICYMI earlier: Pharma's top 10 deals of 2014. Feature | Follow @FiercePharma

@CarlyHFierce: Pharma wanted pricey orphan meds, and now it's got 'em in record numbers. Story | Follow @CarlyHFierce

> FDA grants Celgene's Revlimid new use as it moves toward $10B in sales. Story

> Regeneron's Eylea beats Roche's Lucentis in new head-to-head study. Article

> NICE, drugmakers reject analysis that price watchdog is too generous. Report

Vaccines News

> Advaxis nets $23M in financing for cancer vaccine development. More

> Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot. News

> Novavax's Ebola vaccine is in hot pursuit of GSK, Merck, J&J candidates. Story

> VaxInnate reaps $53M for flu jab trials on BARDA contract extension. Article

> Gates Foundation, WHO fund synthetic polio vaccine development. Report

Pharma Manufacturing News

> Taro recalls nearly 37,000 bottles of children's allergy relief syrup. Article

> WuXi inks deal to borrow $165M to support manufacturing growth. News

> InvaGen Pharma and AlphaMed Bottles building new plants on Long Island. Story

> Protein Sciences cancels expansion plans after governor gets flu shot from foreign competitor. Item

> India mulling plans to build bulk drug manufacturing capacity. Report

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.